Show simple item record

dc.contributor.authorTaprogge, J
dc.contributor.authorWadsley, J
dc.contributor.authorMiles, E
dc.contributor.authorFlux, GD
dc.date.accessioned2021-01-18T11:15:15Z
dc.date.issued2021-02-01
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2021, 33 (2), pp. 131 - 136
dc.identifier.issn0936-6555
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4287
dc.identifier.eissn1433-2981
dc.identifier.doi10.1016/j.clon.2020.12.002
dc.description.abstractMulticentre clinical trials involving a dosimetry component are becoming more prevalent in molecular radiotherapy and are essential to generate the evidence to support individualised approaches to treatment planning and to ensure that sufficient patients are recruited to achieve the statistical significance required. Quality assurance programmes should be considered to support the standardisation required to achieve meaningful results. Trials should be designed to ensure that dosimetry results from image acquisition systems across centres are comparable by incorporating steps to standardise the methodologies used for the quantification of images and dosimetry. Furthermore, it is essential to assess the expertise and resources available at each participating site prior to trial commencement. A quality assurance plan should be drawn up and training provided if necessary. Standardisation of quantification and dosimetry methodologies used in a trial are essential to ensure that results from different centres may be collated. In addition, appropriate uncertainty analysis should be carried out to correct for differences in methodologies between centres. Recommendations are provided to support dosimetry studies based on the experience of several previous and ongoing multicentre trials.
dc.formatPrint-Electronic
dc.format.extent131 - 136
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE LONDON
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleRecommendations for Multicentre Clinical Trials Involving Dosimetry for Molecular Radiotherapy.
dc.typeJournal Article
dcterms.dateAccepted2020-12-02
rioxxterms.versionofrecord10.1016/j.clon.2020.12.002
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))
pubs.issue2
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.)
pubs.publication-statusAccepted
pubs.volume33
pubs.embargo.termsNo embargo
icr.researchteamRadioisotope Physics
dc.contributor.icrauthorTaprogge, Jan


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0